// App-Quantinova.ai

CTNI-09 : A PHASE I HEALTHY VOLUNTEER STUDY ON THE RELATIVE BIOAVAILABILITY AND FOOD EFFECT OF CAPSULE AND GRANULE FORMULATIONS OF SELUMETINIB

Researchers

Presenter

  • Sarit Cohen-Rabbie

Principal Investigators

  • Alexandra Mattinson

  • Karen So

  • Nan Wang

  • Eileen McBride

  • Karthick Vishwanathan

  • Ronald Goldwater

Medical Centers

  • Clinical Pharmacology and Safety Science, R&D, AstraZeneca, Melbourne, United Kingdom

  • Oral Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield, United Kingdom

  • Late Oncology Statistics, AstraZeneca, Cambridge, United Kingdom

  • Clinical Pharmacology and Safety Science, R&D, AstraZeneca, Boston, USA

  • Parexel International, Baltimore, MD, USA

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • Neurofibromatosis type 1

Biomarkers

  • Dual specificity mitogen-activated protein kinase kinase 1

Drug/Treatment

  • ARRY-142886

  • selumetinib

  • AZD-6244

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

  • Cross Over

  • Open Label

  • Single Center

Phase

  • I

Study Id's

  • NCT03649165

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved